cAMPfield launches with $180m as prifemilast enters the crowded IBD race
cAMPfield Therapeutics is backing prifemilast as a better-tolerated oral PDE4 inhibitor for inflammatory bowel disease, but mid-stage trials must prove that selectivity translates into durable remission.